Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of deep brain stimulation of the subthalamic nucleus (DBS-STN) and L-dopa (LD) on cortical activity in Parkinson's disease (PD) are poorly understood.
|
27771287 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine patients with Parkinson's disease underwent DBS implantation in the subthalamic nucleus.
|
31216311 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-contrast hybrid images can be used for precisely directed DBS targeting, e.g., GPi DBS for the treatment of advanced Parkinson's disease.
|
31604332 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
DBS is initially used for treatment of essential tremor and Parkinson's disease in adults.
|
29797064 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To image the pedunculopontine tegmental nucleus (PPN), a deep brain stimulation (DBS) target for Parkinson disease, using MRI with validated results.
|
29532240 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The initial results indicate that the proposed method may be a clinically useful aid for optimal DBS lead placement as well as a new tool in the ongoing scientific search for the optimal DBS target for PD.
|
27982769 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigate whether the ventroanterior (VA) and ventrolateral (VL) motor nuclei of the thalamus can serve as novel and effective DBS targets for PD.
|
30890329 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Education level is associated with DT-related gait changes in PD one year post-DBS.
|
31621623 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence was divided into four categories: medication used in PD management, imaging studies, genetic analysis and subthalamic deep brain stimulation (STN-DBS).
|
22713408 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term effects of STN DBS on the PD motor subtypes.
|
30337863 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report on the feasibility of DBS target localization in the subthalamic nucleus (STN) by long-latency somatosensory evoked potentials (LL-SSEPs) (>40 msec) in Parkinson's disease (PD) patients.
|
29164724 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Veterans Affairs Cooperative Study Program 468 study (CSP 468) produced significant findings regarding deep brain stimulation (DBS) target selection for Parkinson's Disease (PD) treatment, yet its impact on clinical practices has not been described.
|
29249683 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to examine swallowing function in patients with Parkinson's disease before and after caudal zona incerta deep brain (cZI DBS) surgery.
|
28638714 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET).
|
30875687 |
2019 |
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On an individual level, participants with PD exhibited heterogeneous changes with DBS stimulation.
|
29032347 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whilst changes in the frequency of subthalamic deep brain stimulation (STN-DBS) have been proposed to improve control of tremor or axial motor features in Parkinson's disease (PD), little is known about the effects of frequency changes on upper limb motor function, particularly bradykinesia.
|
29614696 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found different metabolic changes during DBS-STN among patients with PIGD, concerning brain regions that are already known to be involved in gait disorders in Parkinson's disease, suggesting that DBS is responsible for the appearance of PIGD.
|
31350641 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate how the frequency settings of deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) influence the motor symptoms of Parkinson's disease (PD).
|
30262859 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recruited 15 patients with Parkinson's disease undergoing subthalamic DBS for local field potential recordings after electrode implantation, and at 3 and 8months post-operatively using the implantable sensing enabled Activa PC+S (Medtronic).
|
29031219 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This case report presents a 54-year-old Parkinson´s disease patient who underwent a DBS implantation to the subthalamic nuclei bilaterally.
|
31852004 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the existence of placebo and micro-lesion effects has been convincingly demonstrated in DBS for major depression and Parkinson's disease, systematic investigations for obsessive-compulsive disorder (OCD) are currently lacking.
|
31383848 |
2019 |
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report on a patient with advanced PD due to R793M missense mutation in the LRRK2 gene successfully treated by STN-DBS.
|
20177695 |
2010 |